Jiaying Chen is a sixth-year PhD candidate from Hangzhou, China, studying genetics at Yale, and joined F-Prime as one of our summer Fellows and Interns. Her go-to lunch option in Cambridge during her time here was Tatte (where else?), and she enjoyed kayaking on the Charles River, watching Fourth of July fireworks, and exploring the Boston food scene. We caught up to reflect on the work she did with us over the summer. Q: What did you work on while you were at F-Prime? A: I primarily worked on a landscaping project where I compiled bispecific assets in development for inflammation and immunology, and identified several promising lead assets for potential investment opportunities. Additionally, I contributed to the scientific due diligence of ongoing deals, led several interviews with key opinion leaders (KOL), and participated in introductory calls with prospective biotech companies. I truly enjoyed the process of identifying the “gold” among the vast assets in development through scientific due diligence and KOL interviews. It was incredibly rewarding to see how my efforts in scientific due diligence contributed to an investment decision. Q: What surprised you most about working in venture capital? A: The most surprising aspect of biotech venture capital that I experienced during this fellowship is the breadth and depth of science involved in due diligence, as well as how collaborative the process is for biotech investment and company formation. Q: Have your career aspirations changed as a result of this experience? A: This fellowship has reinforced my career aspiration to become a biotech investor. Seeing the promising clinical outcomes of next-generation drugs in development during my fellowship has deepened my conviction in the importance of supporting companies that are creating novel therapeutics for diseases with high unmet needs.
F-Prime Capital
Venture Capital and Private Equity Principals
Cambridge, MA 20,113 followers
We create and invest in healthcare and technology companies that impact lives all over the world.
About us
Our roots are in one of America’s great entrepreneurial success stories. Fidelity Investments was founded in 1946 and grew from a single mutual fund into one of the largest asset management firms in the world, with over $2 trillion in assets under management. For the last forty years, our venture capital group has had the privilege of backing other great entrepreneurs as they built ground-breaking companies in technology and life sciences, including Atari, MCI, ROLM Corp., Alibaba, Ironwood Pharmaceuticals, and Ultragenyx. Today our funds are larger and more global, but our teams are still small and local. We stay true to our entrepreneurial roots. In the US and Europe, we are F-Prime Capital investing in healthcare (formerly Fidelity Biosciences) and in technology (formerly part of Devonshire Investors). In other geographies, our sister fund is called Eight Roads (formerly Fidelity Growth Partners), with investment teams in London, Shanghai, Beijing, Hong Kong, Tokyo, and Mumbai. Together we bring a world of insight, domain expertise and relationships to support our entrepreneurs. Without the pressure of fundraising from outside investors, we focus all of our time finding and helping great entrepreneurs build important companies.
- Website
-
http://fprimecapital.com/
External link for F-Prime Capital
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 11-50 employees
- Headquarters
- Cambridge, MA
- Type
- Privately Held
Locations
-
Primary
One Main Street
Cambridge, MA 02142, US
Employees at F-Prime Capital
Updates
-
Carlson Mummert is a Masters of Science in Technology Management candidate at Columbia University, originally from Munich, Germany. He found out about F-Prime after Abdul Abdirahman spoke at a Columbia panel on entrepreneurship and the state of startups and venture, and joined our 2024 Summer Fellowship Program as a venture fellow. He's pictured below with the tech team on Boston Harbor. During his time in the Boston area, Carlson enjoyed hiking and swimming at Morse Pond, and spotted five humpback whales on a whale watching trip! Q: What kind of work did you do at F-Prime? A: I rotated between the fintech and crypto/web3 teams. For the fintech team, I assisted in a research project on the impact of AI on various banking functions and updated the F-Prime Fintech Index based on FY24 business performance to date. On the crypto/web3 team, I supported the diligence of ongoing deals and led the formation of an investment thesis into the relatively nascent DePIN sector. I enjoyed the variety of job content and the ability to introduce and follow-up on new ideas. Q: How has the summer internship helped to crystallize your vision for your post-college career? A: The bird’s eye view that VC provides allowed me to establish a comprehensive landscape of the different types of problems founders are trying to solve and how I can provide the most value. The sheer number of companies you screen and conduct diligence on before deciding whether to invest was the most surprising part of working in venture capital. Q: Have your career aspirations changed as a result of this experience? A: This internship solidified my aspiration to work within venture capital, because of the dynamic nature of the industry, the intellectual challenge of assessing companies and management teams and the innovative approaches founders are taking to solve complex challenges. I’m looking forward to applying my Masters education to invest in and support entrepreneurs in the tech sector.
-
-
Congratulations, Nate Holiday and Scott Dykstra on Space and Time's $20M raise! We're excited to partner with you on this mission to bring the immutability of blockchain to AI applications. Read more here: https://lnkd.in/gx_ga_3A
-
-
This summer, F-Prime welcomed a new group of interns and fellows to our Cambridge offices for our 2024 Summer Internship/Fellowship Program. Over the next couple of weeks, we’re excited to have them share some of their experiences during the last several months with us. First up is Marlíse Arellano Sutton, a Harvard Business School candidate from Austin, Texas. Q: How did you learn about F-Prime, and why did you decide to join as an MBA intern? A: I saw F-Prime present at a HBS Healthcare Club Event, during which the team could have easily glossed over the background on VC and spent more time on the firm. Instead, they took time out of their presentation to explain VC and its mechanics to the group. Many of my peers noted how grateful they were for this, because they are pivoting to VC and the background information was incredibly helpful. To me, it demonstrated F-Prime’s commitment to mentorship and education and pushed me to apply. I decided to join the team because, throughout the interview process and my internship, I felt the team was genuinely invested in my learning and growth. This value system permeates F-Prime, as they are focused on learning from one another and the rest of the healthcare sector. Q: What kind of work did you do at F-Prime? A: I had the opportunity to work with a portfolio company, complete a deep-dive on an area in healthcare I was passionate about, and support the deal process for potential investments. I learned from and enjoyed all of this work, but was particularly excited that I had the chance to share my deep dive into pediatric severe mental illness with the whole healthcare team in my final weeks at the firm. That discussion encapsulated the great experience I have had at F-Prime. Everyone here is a lifelong learner and approaches topics with “actionable curiosity” — asking deep questions and providing even deeper answers and suggestions, whether it is on a simple question or how to reshape the care system to better serve children experiencing mental health crisis. Q: What surprised you most about working in venture capital? A: Although this was not surprising to me, I loved the constant drive F-Prime had for solving healthcare’s toughest problems. I also appreciated the mission-driven aspect of the investment process, focusing on clinical outcomes as well as the ROI a company could provide. As someone who has now worked on the VC and hospital side of the table, I am excited to see VC firms like F-Prime pushing the innovation envelope in healthcare and working with hospitals, government, payors, and others to make the healthcare system better for everyone.
-
-
Congratulations to AviadoBio and Neumora for being named in Labiotech.eu‘s “10 neuroscience biotech companies you should know about” list! This list highlights the most promising small biotech companies that are tackling the formidable challenges of developing treatments for neurological diseases. Learn more: https://lnkd.in/ddA2m5GQ Stacie Weninger, Ph.D. │ Nihal Sinha, M.D. │ Martin Taylor, Ph.D. #healthcare #neuroscience #biotech
-
Congratulations to Kristina Saffran, Erin Parks, Ph.D., and the Equip team for being featured in Forbes as one of the 2024 Next Billion-Dollar Startups. The list annually showcases U.S.-based private companies on track to achieve a $1 billion valuation, highlighting their potential as the next major industry disruptors. See the full list here: https://lnkd.in/eADCXisD Additionally, Equip CEO and co-founder Kristina Saffran shared with Forbes how her own recovery from anorexia revealed a gap in effective eating disorder treatment, driving the formation of Equip and its growth to become the leading provider of accessible, evidence-based eating disorder care. Learn more: https://lnkd.in/g4CcY_8C Jon Lim │ Brett Cook #BillionDollarStartups #healthcare #eatingdisorders #startup
Next Billion-Dollar Startups 2024
social-www.forbes.com
-
F-Prime Capital reposted this
Do you think India will be swept up in the $100Bn global surge of anti-obesity drugs? Join us at #ScaleUpHealth2024 as we hear this expert panel discuss this very question and share their views. Keep all your questions ready. We have limited seats, so if you haven’t already registered your interest to attend, follow this link – https://lnkd.in/g47wdgSF 🔸 Vikrant Shrotriya, Managing Director & Corporate Vice President, Novo Nordisk India 🔸 Dr. Shashank Joshi, Endocrinologist & President of Indian Academy of Diabetes 🔸 Madan Somasundaram, Co-founder & CEO, sugar.fit 🔸 Carl Bradford Byers 🚑, Partner, F-Prime Capital Eight Roads, McKinsey India #healthcare #conference #antobesity #events #scaleup #founders #lifesciences #entrepreneurs
-
-
F-Prime Capital reposted this
What a heartwarming and inspiring night 🥹 Last night, I had the privilege of gathering with 12 extraordinary senior women leaders in Fintech and Finance, each at different stages of their careers and personal lives. We shared stories of cross-connections at PayPal, Visa, and Wells Fargo, the joys and challenges of new parenthood, raising video game-loving teenagers, navigating career transitions, and discovering fellow Portuguese speakers. I’m endlessly inspired by each of these incredible women who embrace courage and vulnerability, put themselves out there, and live by the “Just Do It” mentality. As we celebrate the Paris Olympics achieving gender parity, I’m filled with hope that we can one day reach the same milestone in Fintech and Finance. When we support and uplift each other, we all rise together. Thank you for sharing the beautiful night with me and Sarah Lamont! Camilla Matias at Brex Yi Liu at Gusto Jessica Chiu at Airwallex Laura Fragomeni at Block Daniela Barbosa at The Linux Foundation Trisha Kothari at Unit21 Arthi Rajan Makhija at Pinch AI Cristina Etcheberry at Toku Mary Dent at Klaros Group Reetika Grewal at Wells Fargo Priya Nanduri at Visa Sara Wardell-Smith at Axos Financial
-
-
Congratulations to Ray Smets and the entire Quantum Circuits, Inc. team on securing your Series B investment round. This investment will support Quantum Circuits as they revolutionize the quantum computing industry with their first-of-its-kind dual-rail qubit featuring built-in error detection. Their innovative approach enables the fidelity, speed, and scalability needed for commercially viable quantum computers. “We see many quantum companies taking different approaches to solving the error correction challenge with varying degrees of success,” said Stephen Knight, M.D., President and Senior Managing Partner at F-Prime Capital. “Quantum Circuits leverages the speed, flexibility, and scalability of this approach to build high-fidelity systems that have the potential to be best-in-class.” Learn more: https://lnkd.in/gTbHxQmP ARCH Venture Partners │ Sequoia Capital │ Hither Creek Ventures │ Canaan │ Fitz Gate Ventures │ IQT (In-Q-Tel) │ Osage University Partners (OUP) │ Connecticut Innovations │ Tao Capital │ Tribeca Venture Partners Stephen Knight, M.D. │ Robert Weisskoff, Ph.D. │ Mike Feng #computing #technology #innovation
Yale Spinout in Quantum Field Draws US Intelligence Agency Money
bloomberg.com
-
Congratulations to our portfolio companies 1upHealth, Inc., AvantStay, Capital Rx, ConnexPay, Embark Veterinary, and Vestwell on being named in the 2024 Inc. 5000 list: ▪️ 1upHealth - https://lnkd.in/emvPQuxx ▪️ AvantStay - https://lnkd.in/emC2Q87m ▪️ Capital Rx - https://lnkd.in/eAhJyiwc ▪️ ConnexPay - https://lnkd.in/eJJ2cGPy ▪️ Embark Veterinary - https://lnkd.in/eb_AfHVz ▪️ Vestwell - https://lnkd.in/efXginEc The 2024 Inc. 5000 list is an annual ranking by Inc. Magazine that highlights the fastest-growing private companies in the U.S., based on their revenue growth over the past three years. Learn more: https://lnkd.in/g6Yn3rnH Sean Breuner │ A. J. Loiacono │ Ben Peters │ Amish Desai │ Aaron Schumm David Jegen │ Carl Bradford Byers 🚑 │ Abdul Abdirahman │ Brett Cook │ Jay Farber │ Gaurav Tuli #Inc5000 #tech #healthcare
-